Is TB-500 FDA-approved?

TB-500 is not the molecule that has a clinical record

Almost every page that asks whether TB-500 is approved answers by describing research on thymosin β4, a 43-amino-acid protein found throughout human tissue. That is a different substance. TB-500 is a short synthetic fragment derived from it, and the regulators that have looked at both treat them as distinct.

The World Anti-Doping Agency makes the relationship explicit: its 2026 Prohibited List bans “thymosin-β4 and its derivatives” under S2.3 and names TB-500 as the example of a derivative. RegeneRx, the company that has spent two decades developing the full-length peptide, describes its own pipeline as “Tβ4 and its constituent fragments” — again, two categories, not one.

The naming record says the same thing more sharply. In September 2018 the World Health Organization recommended an International Nonproprietary Name for thymosin β4: timbetasin. Any drug substance with those characteristics developed as a pharmaceutical from that point on must use it. TB-500 has no INN and no United States Adopted Name — and the absence of a USAN was one of the specific objections FDA review staff raised against all seven peptides at the July 2026 advisory committee meeting.

What the thymosin β4 record actually shows

This is the part worth knowing, because it is the strongest available evidence about the family — and it is not encouraging for the uses TB-500 is sold for.

The FDA granted orphan drug designation to “Thymosin beta 4” on 31 December 2013, sponsored by ReGenTree LLC, for the treatment of neurotrophic keratopathy — a rare corneal disease. Orphan designation is an incentive to develop a drug for a rare condition; it is not an approval and confers no authorization to market. The designation is still listed as designated, not approved. That is more than twelve years of development on the most favorable regulatory terms the FDA offers, without reaching approval.

The clinical results are mixed, and the site reports them as such. A Phase 3 trial (SEER-1) published in International Journal of Molecular Sciences in January 2023 reported complete corneal healing at four weeks in six of ten treated patients against one of eight on placebo. Those are single-digit numbers. Two confirmatory Phase 3 trials followed. In June 2025 the sponsor announced that SEER-3 missed its primary endpoint — no statistically significant difference in complete corneal healing at four weeks — attributing the result to a stronger-than-expected placebo response. SEER-2 was still running as of September 2026 with no results reported.

Note what every one of those trials has in common: the drug is an ophthalmic solution — eye drops — studied in a rare corneal disease. None of them studies an injection, and none of them studies wound healing, which is the use TB-500 is marketed for and the indication the advisory committee voted on in July 2026. The clinical record that exists does not transfer.

What approval would actually require

A drug reaches the US market through an Investigational New Drug application, then Phase 1, 2 and 3 trials, then a New Drug Application or Biologics License Application that the FDA reviews and approves. Nothing resembling that sequence has been started for TB-500 by any sponsor.

Chemistry is the other half, and it is where the FDA’s own reviewers were blunt. At the July 2026 meeting, review staff recommended against all seven peptides — including TB-500 — on grounds that had little to do with whether they work: no United States Adopted Name, incomplete physical and chemical characterization, unknown impurity profiles arising from solid-phase peptide synthesis, and a risk of immunogenicity from peptide aggregation in injectable products. The committee voted 8–6 with one abstention to recommend TB-500 anyway, against that advice.

Those objections describe work that has not been done. Until it is, the approval question is not close.

Why the July 2026 vote is not a step toward approval

This is the most common misreading of what happened, and it matters more than anything else on this page. Compounding eligibility and drug approval are two separate statutory pathways.

Approval runs through section 505 of the Federal Food, Drug, and Cosmetic Act: trials, an application, an FDA decision. Compounding runs through section 503A, which lets a licensed pharmacy prepare a medicine from a bulk substance that appears on an FDA list — precisely because the substance is not an approved drug. A substance can sit on that list forever and never become approved. Reaching the list is not progress toward approval; it is an alternative to it.

So even in the best case for TB-500 — the FDA opens rulemaking, publishes a proposed rule, runs a comment period and issues a final rule adding it to the 503A list — TB-500 would still not be an FDA-approved drug. It would be a substance a pharmacy may compound to a prescription. As of September 2026 the FDA has not taken the first of those steps. Our explainer on US peptide regulation sets out how the two pathways differ and why the rulemaking timeline runs to 2027 at the earliest.

The evidence, graded honestly

For TB-500 itself, in the form and for the uses it is sold for, there is no controlled human evidence to grade. For the parent molecule there is real Phase 3 data, in a different formulation and a different disease, and the most recent large trial of it failed. Anyone citing “clinical trials” as support for injected TB-500 is either describing eye drops for corneal disease or describing animal studies.

Primary sources: FDA Orphan Drug Designations and Approvals database — “Thymosin beta 4”, designated 31 December 2013, ReGenTree LLC, neurotrophic keratopathy, not approved · WHO recommended INN “timbetasin” for thymosin beta 4 (September 2018) · WADA 2026 Prohibited List, S2.3 · FDA Advisory Committee Calendar and Federal Register docket FDA-2025-N-6895 (PCAC, 23–24 July 2026) · SEER-1 Phase 3 results, Int J Mol Sci 2023;24:554 · SEER-3 Phase 3 topline, sponsor announcement June 2025 · sections 503A and 505 of the FD&C Act.